文献速递神经头颈PETCTMR

甲硫氨酸PET在脑肿瘤与非肿瘤性占位病变诊断中的表现:426例单中心报告

Methionine PET Findings in the Diagnosis of Brain Tumors and Nontumorous Mass Lesions: A Single-Center Report on 426 Cases.
PubMed 文献 · AJNR Am J Neuroradiol · 2025-12-04

单中心回顾性分析426例未确诊脑病变患者的MET-PET,以TNR≥1.5为阳性阈值,肿瘤检出敏感度86.2%、特异度47.4%,多发性硬化阳性率高,IDH野生型胶质母细胞瘤TNR高于IDH突变型胶质瘤,少突胶质细胞瘤TNR高于星形细胞瘤且与分级相关。

要点

  • MET-PET以TNR≥1.5为阳性阈值时,肿瘤检出敏感度86.2%、特异度47.4%。
  • 多发性硬化病例MET-PET阳性率高达10/12,显著高于其他非肿瘤性病变。
  • IDH野生型胶质母细胞瘤TNR显著高于IDH突变型胶质瘤,少突胶质细胞瘤TNR高于星形细胞瘤。

核心结论

  • MET-PET对脑肿瘤检测具有高敏感度,但特异度有限,源于炎症性病变的假阳性和低级别肿瘤的假阴性。
  • 作者认为应将MET-PET与其他影像模态整合以提高诊断准确性。

研究设计与样本

  • 单中心回顾性研究,纳入2019年1月至2024年5月间连续426例未确诊脑病变并接受MET-PET检查的患者。
  • 以肿瘤/正常区域比值(TNR)≥1.5为阳性阈值,组织学诊断依据世界卫生组织2021标准,包括IDH突变状态和1p/19q共缺失。

关键影像表现/征象

  • 342例(67.8%)确诊为肿瘤性病变,76例(17.8%)为非肿瘤性病变,61例(14.3%)未确诊。
  • 多发性硬化病例MET-PET阳性率为10/12,显著高于其他非肿瘤性病变。
  • IDH野生型胶质母细胞瘤TNR显著高于IDH突变型胶质瘤,少突胶质细胞瘤TNR高于星形细胞瘤。
  • 星形细胞瘤中TNR值与肿瘤分级相关。

诊断标准与关键数值

  • MET-PET阳性阈值定义为TNR≥1.5。
  • 肿瘤检测敏感度86.2%,特异度47.4%。

临床应用与阅片要点

  • MET-PET高敏感度但低特异度,炎症性病变可出现假阳性,低级别肿瘤可出现假阴性。
  • 作者认为应将MET-PET与其他影像模态整合以提高诊断准确性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Differentiating between a brain tumor and a nontumorous lesion remains a diagnostic challenge, particularly when conventional imaging modalities such as CT and MRI provide inconclusive results. While 11C-methionine PET (MET-PET) has shown potential in neuro-oncology, its diagnostic performance across a broad spectrum of brain pathologies has not been comprehensively evaluated. This study, therefore, assessed the sensitivity, specificity, and uptake patterns of MET-PET in a large cohort of brain lesions.

MATERIALS AND METHODS: This single-center retrospective study analyzed 426 consecutive patients with undiagnosed brain lesions who underwent MET-PET imaging between January 2019 and May 2024. Tumor-to-normal region ratios (TNRs) were calculated by using a threshold of 1.5 for positive findings. Histologic diagnoses were established on the basis of the World Health Organization 2021 criteria, including isocitrate dehydrogenase (IDH) mutation status and 1p/19q-codeletion.

RESULTS: Among the cohort, 342 cases (67.8%) were confirmed as having tumorous lesions; 76 (17.8%), as having nontumorous lesions; and 61 (14.3%) remained undiagnosed. MET-PET exhibited high sensitivity (86.2%) but limited specificity (47.4%) for tumor detection. In multiple sclerosis cases, MET-PET showed a remarkably high positivity rate (n = 10/12) that was significantly higher than for other nontumorous lesions. In terms of tumors, IDH wild-type glioblastomas had significantly higher TNRs compared with IDH-mutant gliomas, while oligodendrogliomas had higher TNRs compared with astrocytomas, in which TNR values correlated with tumor grade.

CONCLUSIONS: MET-PET demonstrated robust sensitivity for brain tumor detection but was limited by low specificity due to false-positives in inflammatory conditions and false-negatives for low-grade tumors. These findings imply the importance of integrating MET-PET with other imaging modalities to enhance diagnostic accuracy.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Shiba Y, Aoki K, Ohka F, et al. Methionine PET Findings in the Diagnosis of Brain Tumors and Nontumorous Mass Lesions: A Single-Center Report on 426 Cases. AJNR Am J Neuroradiol. 2025. PMID: 40506233. doi:10.3174/ajnr.A8871

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。